Status:
COMPLETED
PF-04634817 Renal Impairment Study
Lead Sponsor:
Pfizer
Conditions:
Renal Insufficiency
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment. This study will i...
Eligibility Criteria
Inclusion
- Male or female (non child bearing potential aged 18-75 years
- Documented renal impairment (mild, moderate or severe using Cockcroft-Gault equation) or matched healthy volunteers (age, weight and gender)
Exclusion
- Subjects with acute renal failure
- Subjects receiving, or likely to receive, CYP450 3A4 inhibitors
- Abnormal ECG at screening
Key Trial Info
Start Date :
May 10 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 3 2013
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01791855
Start Date
May 10 2013
End Date
September 3 2013
Last Update
March 1 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Avail Clinical Research, LLC
DeLand, Florida, United States, 32720
2
Unversity of Miami
Miami, Florida, United States, 33136